Case Reports in Pathology

Case Reports in Pathology / 2013 / Article

Case Report | Open Access

Volume 2013 |Article ID 784176 |

Jason B. Kern, Deiter J. Duff, Jamie L. Odem, Magda Esebua, Lisa R. Smith, Donald Doll, Michael Wang, "A Novel del(20q) in Aggressive Nodal Marginal Zone Lymphoma", Case Reports in Pathology, vol. 2013, Article ID 784176, 4 pages, 2013.

A Novel del(20q) in Aggressive Nodal Marginal Zone Lymphoma

Academic Editor: M. Mazzocchi
Received23 Nov 2012
Accepted16 Dec 2012
Published12 Feb 2013


This is a case report of a previously undescribed 20q chromosomal deletion (del(20q)) in marginal zone lymphoma (MZL). A 54-year-old Caucasian male presented with an enlarging neck mass and multiple violaceous skin nodules over his chest. Biopsy of the neck mass and cervical lymph nodes revealed MZL. Cytogenetic evaluation of both lymph node and bone marrow tissue revealed del(20q). This was an unexpected finding, as del(20q) is associated with myelodysplastic syndromes and myeloproliferative neoplasms and rarely seen in diffuse large B-cell lymphoma, follicular lymphoma, and T-cell lymphoma, but has not previously been described in MZL. We describe the case presentation and histologic findings and discuss the significance of this novel finding.

1. Introduction

20q chromosomal deletion (del(20q)) is a well-described cytogenetic abnormality in myeloid neoplasms such as myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), and the myeloproliferative neoplasms (MPN) [1]. Del(20q) is rare in lymphomas, but has been detected in cases of diffuse large B-cell lymphoma, follicular lymphoma, and T-cell lymphoma [1]. A literature search and the National Cancer Institute’s Recurrent Chromosome Aberrations in Cancer Database failed to reveal any reported cases of del(20q) in marginal zone lymphoma (MZL) [2]. Here we present the first reported case of MZL with del(20q), detected by FISH in lymph node tissue and by karyotyping in involved bone marrow tissue.

2. Case Presentation

The patient is a 54-year-old Caucasian man with a slowly enlarging neck mass, accompanied by multiple violaceous skin nodules over his chest and neck and B symptoms. Physical exam revealed an  cm tender, erythematous right neck mass as well as multiple violaceous, mobile skin nodules on the neck and chest. Splenomegaly was not present. Also of note, the patient is hepatitis C virus positive, which is associated with MZL [3]. A CT of the neck revealed a large, poorly defined right neck mass measuring up to 9 cm as well as many enlarged cervical lymph nodes. An open biopsy was performed and a right posterior cervical lymph node and tissue from the deep neck mass were sent for histologic evaluation.

Microscopic examination showed almost complete effacement of the node (Figure 1(A)). Follicles were replaced by atypical monocytoid cells (Figures 1(B) and 1(C)), which stained positive for PAX-5, CD19, and CD20, but were negative for CD5 and cyclin D1. The effaced area had a MIB-1 labeling index of 10%. BCL-6 and CD23 were diffusely positive in remnant germinal centers which were replaced by atypical monocytoid cells, and these areas corresponded with a negative CD10. These morphologic and immunohistochemical (IHC) findings are characteristic of a nodal MZL [3, 4].The tissue from the deep neck mass revealed similar histology but an area with larger, more hyperchromatic cells (Figures 1(D) and 1(E)) and a higher mitotic rate, with a MIB-1 labeling index of up to 70% (Figure 1(F)). The neoplastic lymphocytes invaded beyond the capsule into the surrounding muscle, consistent with an aggressive morphology [4]. Flow cytometry of the neck mass revealed a monoclonal B-cell population expressing kappa immunoglobulin light chains, CD19 and CD20.

Punch biopsy of one of the skin nodules (Figure 2(A)) showed diffuse involvement of the dermis (Figure 2(B)). The histology showed mostly small monocytoid B cells (Figure 2(C)), again with a classic MZL immunophenotype: BCL6 and CD23 positive in remnant follicles replaced by atypical CD20 positive monocytoid B cells.

Both lymph node and bone marrow tissues were sent for cytogenetic evaluation. FISH on representative lymph node tissue revealed del(20q), near 20q12 (Figure 3(A)). There was not morphologic evidence of MZL in the bone marrow nor any myeloid neoplasm or other 20q deletion-associated disease identified. However, a karyotype of the bone marrow aspirate also revealed a del(20q), near 20q11.2 (Figure 3(B)). This may represent an enrichment of MZL cells during cell culture and molecular evidence of MZL involvement in the bone marrow. The patient was treated with bendamustine plus rituximab and responded well with a complete remission.

3. Discussion

Nodal MZL is one of three subtypes of MZL and its incidence is relatively rare, comprising only 1.5% of all lymphomas [3], characterized by its monocytoid tumor cells in an expanded marginal zone of lymph node. Disease onset is usually around 60 years of age, typically involves cervical and/or inguinal lymph nodes, and is often of advanced stage at diagnosis. Immunophenotype is CD19+, CD20+, PAX5+, BCL2+, CD5−, CD23−, and cyclin D1−. Genetic abnormalities are common, including trisomy 3, trisomy 7, trisomy 12, trisomy 18, and del6q [3]. Other less common abnormalities include losses and/or gain in chromosomes 1, 4, 6, 7, 8, 13, and 21, but not 20 [5].

The finding of a del(20q) in both the lymph node tissue and bone marrow samples was an unexpected finding in this case; a diagnosis of nodal MZL could confidently be made by lymph node histological features, IHC and flow cytometric immunophenotyping. The literature has not previously reported del(20q) in MZL. This finding may represent a specific cytogenetic abnormality in this nodal MZL with an aggressive morphology and high-stage disease. In conclusion, this case of nodal MZL with 20q deletion is a novel finding which can expand the breadth of knowledge of chromosomal abnormalities in MZL.


The authors thank Drs. Jack D. Jones and James T. Edinger for their contribution in the pathological diagnosis of this case.


  1. M. Okada, Y. Suto, M. Hirai et al., “Microarray CGH analyses of chromosomal 20q deletions in patients with hematopoietic malignancies,” Cancer Genetics, vol. 205, pp. 18–24, 2012. View at: Google Scholar
  2. National Cancer Institute, “The Recurrent Chromosome Aberrations in Cancer Database,” 2012, View at: Google Scholar
  3. A. Traverse-Glehen, F. Bertoni, C. Thieblemont et al., “Nodal marginal zone B-Cell lymphoma: a diagnostic and therapeutic dilemma,” Oncology, vol. 26, pp. 92–99, 103–104, 2012. View at: Google Scholar
  4. P. Kaur, “Nodal marginal zone lymphoma with increased large cells: myth versus entity,” Archives of Pathology & Laboratory Medicine, vol. 135, pp. 964–966, 2011. View at: Google Scholar
  5. A. Rinaldi, M. Mian, E. Chigrinova et al., “Genome-wide DNA profiling of marginal zone lymphomas identifies subtype-specific lesions with an impact on the clinical outcome,” Blood, vol. 117, no. 5, pp. 1595–1604, 2011. View at: Publisher Site | Google Scholar

Copyright © 2013 Jason B. Kern et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Related articles

No related content is available yet for this article.
 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

No related content is available yet for this article.

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.